Intraperitoneal chromic phosphate in peritoneoscopically confirmed stage I ovarian adenocarcinoma.
From December 15, 1975 to June 16, 1980, 20 evaluable patients with International Federation of Gynaecology and Obstetrics Stage I invasive adenocarcinoma of the ovary were entered into a prospective study, including pretherapy restaging peritoneoscopy followed by treatment with intraperitoneal chromic phosphate if there was no evidence of residual macroscopic tumor. During a follow-up of 1 1/2 to 6 years (median, 3 years and 1 month), the survival rate without evidence of recurrent ovarian carcinoma was 95%. Moreover, there was a total absence of complications with the use of the sequential steps of pretherapy peritoneoscopy, a normal preinjection peritoneogram, injection of chromic phosphate in large volumes of solution, frequent change of position of the patient after injection, and abdominal scans after injection. This method appears to be safe and is associated with a significantly high survival rate.
D000230:Adenocarcinoma / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D002857:Chromium / Q000008:administration & dosage*; D017608:Chromium Compounds; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007274:Injections, Intraperitoneal; D010535:Laparoscopy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000532:radiotherapy*; D010710:Phosphates / Q000008:administration & dosage*; D011379:Prognosis; D011446:Prospective Studies
D017608:Chromium Compounds; D010710:Phosphates; D002857:Chromium; C509369:chromic phosphate